164 filings
Page 4 of 9
6-K
iptgg031
15 Apr 19
Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 In Sézary Syndrome Patients
7:00am
6-K
1pamln
11 Apr 19
Current report (foreign)
7:00am
6-K
3fxygd0
8 Apr 19
Trillium Therapeutics to Present at Investor Conferences In April
7:06am
6-K
7rq4a47 cr
2 Apr 19
Current report (foreign)
7:14am
6-K
9skcq8cjj ij3
27 Mar 19
Trillium Therapeutics to Unveil Its Sting Agonist Program at the Aacr Annual Meeting 2019
5:01pm
6-K
yo2ej8w7
11 Mar 19
Consolidated Financial Statements
5:04pm
6-K
gbj9z1cg4mkn1rdnfmru
8 Mar 19
Current report (foreign)
5:00pm
6-K
1q6ztx7yd a5zh92z
25 Feb 19
Current report (foreign)
5:05pm
6-K
lnokuwcfwd0
22 Feb 19
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series Ii Non-voting Convertible First Preferred Share Units
9:01am
6-K
z7pruccecs1
21 Feb 19
Trillium Announces Proposed Public Offering of Common Share Units and Series Ii Non-voting Convertible First Preferred Share Units
4:05pm
6-K
imc5w
3 Dec 18
Current report (foreign)
7:00am
6-K
orrgzzvj
14 Nov 18
Interim Condensed Consolidated Financial Statements
7:00am
6-K
wb27k
28 Sep 18
Current report (foreign)
7:19am
6-K
r3kso
27 Sep 18
Trillium Therapeutics to Present at Upcoming Investor Conferences
12:00am
6-K
bvl0 czus
12 Sep 18
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16thAnnual Discovery on Target Conference
12:00am
6-K
cxxq smg68v
30 Aug 18
TRILLIUM TO PRESENT AT THE 20th ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE
12:00am
6-K
pukpr1 fia
8 Aug 18
Interim Condensed Consolidated Financial Statements
7:00am
6-K
kfrj20u h4
25 Jun 18
Form 51-102F3 Material Change Report
10:34am
6-K
c6ml7majd hsb6u
20 Jun 18
Current report (foreign)
12:00am
6-K
ngme4v7sgph8 j4j
20 Jun 18
Current report (foreign)
12:00am